Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the apixaban market right now?

The apixaban market has grown substantially in recent years. It will increase from $2.92 billion in 2024 to $3.19 billion in 2025, at a compound annual growth rate (CAGR) of 9.2%. This growth is due to the higher incidence of atrial fibrillation, the aging population, regulatory approvals, favorable clinical outcomes, and the transition from warfarin to newer oral anticoagulants (NOACs).

How fast Is the apixaban market expected to grow, and what’s its future value?

The apixaban market is expected to see strong growth, reaching $4.48 billion by 2029 at a CAGR of 8.8%. Growth is attributed to the continued rise in cardiovascular diseases, greater awareness and diagnosis, expansion in emerging markets, the aging global population, and changes in health policies and reimbursements. Key trends include advancements in drug delivery systems, increased research and development, innovation and collaborations, FDA approval of apixaban, and the rise of digital health and telemedicine.

Get your apixaban market report here!

https://www.thebusinessresearchcompany.com/report/apixaban-global-market-report

What are the leading drivers of growth in the apixaban market?

The rising prevalence of cardiovascular disease is projected to fuel the growth of the apixaban market. Cardiovascular disease encompasses a wide range of conditions affecting the heart and blood vessels. The increasing prevalence is linked to sedentary lifestyles, poor diet, and other risk factors. Apixaban is a medication that helps prevent blood clots, reducing the risk of conditions like stroke and deep vein thrombosis. According to the American Heart Association, cardiovascular disease caused 931,578 deaths in the US in 2024, driving the demand for apixaban.

What are the key segments defining the apixaban market?

The apixaban market covered in this report is segmented –

1) By Dosage Form: Capsule, Tablets

2) By Application: Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Capsule: 2.5 mg Capsule, 5 mg Capsule

2) By Tablets: 2.5 mg Tablet, 5 mg Tablet

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15979&type=smp

Who are the key players steering the development of the apixaban market?

Major companies operating in the apixaban market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Company Limited, Fresenius Kabi AG, Hetero Drugs Ltd, Eisai Co. Ltd, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd, Medichem S.A., Centaur Pharmaceuticals Pvt. Ltd., Simson Pharma Limited, OPOCRIN SPA, Pinnacle Life Sciences Private Limited

What emerging trends are influencing the growth of the apixaban market?

Major companies in the apixaban market are focused on creating new products like generic anticoagulant medications to increase affordability and accessibility for patients, while also expanding their market presence. A generic anticoagulant is designed to prevent blood clotting by inhibiting various coagulation factors, thus reducing the risks of stroke and other cardiovascular events. In October 2022, Tiefenbacher Pharmaceuticals, a German healthcare company, introduced a generic version of Apixaban in Canada, helping to make blood clot prevention more accessible and affordable for patients worldwide.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15979

Which regions are most influential in expanding the apixaban market?

North America was the largest region in the apixaban market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the apixaban market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Hepatitis B Virus (HBV) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/hepatitis-b-virus-hbv-global-market-report

Small Cell Lung Cancer Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/small-cell-lung-cancer-therapeutics-global-market-report

Anthracycline Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anthracycline-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: